scispace - formally typeset
I

Ivana Hollan

Researcher at Brigham and Women's Hospital

Publications -  71
Citations -  1706

Ivana Hollan is an academic researcher from Brigham and Women's Hospital. The author has contributed to research in topics: Rheumatoid arthritis & Coronary artery disease. The author has an hindex of 20, co-authored 63 publications receiving 1342 citations. Previous affiliations of Ivana Hollan include Innlandet Hospital Trust & University of Oslo.

Papers
More filters
Journal ArticleDOI

Cardiovascular disease in autoimmune rheumatic diseases

TL;DR: Based on biopsy findings, also inflammation in the myocardium and small vessels may contribute to premature CVD in ARDs (cardiac ischemia and heart failure), and drugs targeting immunologic factors participating in the subintimal inflammation might have a protective effect on CVD.
Journal ArticleDOI

Newly Identified Antiatherosclerotic Activity of Methotrexate and Adalimumab: Complementary Effects on Lipoprotein Function and Macrophage Cholesterol Metabolism

TL;DR: The aim of this study was to investigate the influence of MTX and adalimumab treatment on serum cholesterol efflux capacity (CEC) and CLC in RA patients and to study the in vitro effects of the two drugs on macrophage cholesterol handling.
Journal ArticleDOI

Irisin in blood increases transiently after single sessions of intense endurance exercise and heavy strength training.

TL;DR: The results strongly suggest that single sessions of intense endurance exercise and heavy strength training lead to transient increases in irisin concentrations in blood, and suggest that irisin responses to resistance exercise are higher in individuals with lower proportions of lean body mass.
Journal ArticleDOI

Strength training improves performance and pedaling characteristics in elite cyclists

TL;DR: In conclusion, heavy strength training leads to improved cycling performance in elite cyclists as evidenced by a superior effect size of ES training vs E training on relative improvements in power output at 4 mmol L−1 [la−], peak power output during 30‐s Wingate test, Wmax, and mean power output During 40‐min all‐out trial.